BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,646,111 | -7.3% | 611,813 | +11.1% | 0.03% | +12.5% |
| Q2 2023 | $44,947,355 | -15.4% | 550,623 | -23.1% | 0.02% | -20.0% |
| Q1 2023 | $53,108,615 | +3.5% | 715,846 | +15.7% | 0.03% | 0.0% |
| Q4 2022 | $51,289,459 | -14.3% | 618,840 | +193.8% | 0.03% | -16.7% |
| Q3 2022 | $59,821,000 | +41.2% | 210,633 | +72.3% | 0.04% | +50.0% |
| Q2 2022 | $42,378,000 | -22.6% | 122,255 | -3.3% | 0.02% | -7.7% |
| Q1 2022 | $54,722,000 | +0.5% | 126,369 | +20.0% | 0.03% | +8.3% |
| Q4 2021 | $54,465,000 | +13.4% | 105,280 | +6.2% | 0.02% | +4.3% |
| Q3 2021 | $48,048,000 | +61.2% | 99,154 | +49.8% | 0.02% | +64.3% |
| Q2 2021 | $29,804,000 | +515.9% | 66,196 | +422.4% | 0.01% | +366.7% |
| Q1 2021 | $4,839,000 | +80.3% | 12,671 | +49.9% | 0.00% | +50.0% |
| Q4 2020 | $2,684,000 | +69.3% | 8,452 | +32.0% | 0.00% | +100.0% |
| Q3 2020 | $1,585,000 | -66.3% | 6,402 | -64.1% | 0.00% | -75.0% |
| Q2 2020 | $4,710,000 | -59.5% | 17,834 | -70.9% | 0.00% | -60.0% |
| Q1 2020 | $11,617,000 | -34.9% | 61,267 | -24.6% | 0.01% | -16.7% |
| Q4 2019 | $17,842,000 | +81.7% | 81,300 | +62.0% | 0.01% | +71.4% |
| Q3 2019 | $9,817,000 | -18.3% | 50,186 | -12.9% | 0.01% | 0.0% |
| Q2 2019 | $12,012,000 | +120.9% | 57,622 | +110.3% | 0.01% | +133.3% |
| Q1 2019 | $5,437,000 | -76.4% | 27,397 | -82.8% | 0.00% | -81.2% |
| Q4 2018 | $23,013,000 | -0.5% | 159,043 | +40.4% | 0.02% | +128.6% |
| Q3 2018 | $23,124,000 | -6.1% | 113,309 | -32.0% | 0.01% | 0.0% |
| Q2 2018 | $24,637,000 | +489.3% | 166,553 | +501.3% | 0.01% | +250.0% |
| Q1 2018 | $4,181,000 | -61.3% | 27,697 | -66.8% | 0.00% | -71.4% |
| Q4 2017 | $10,790,000 | +13.8% | 83,314 | +6.2% | 0.01% | +16.7% |
| Q3 2017 | $9,478,000 | +28.9% | 78,423 | +25.3% | 0.01% | +20.0% |
| Q2 2017 | $7,352,000 | +28.4% | 62,601 | +11.1% | 0.01% | +25.0% |
| Q1 2017 | $5,727,000 | -55.3% | 56,371 | -54.8% | 0.00% | -60.0% |
| Q4 2016 | $12,808,000 | -28.0% | 124,582 | -23.3% | 0.01% | -23.1% |
| Q3 2016 | $17,791,000 | +40.4% | 162,507 | +44.6% | 0.01% | +44.4% |
| Q2 2016 | $12,672,000 | +16.2% | 112,393 | -2.6% | 0.01% | +12.5% |
| Q1 2016 | $10,905,000 | +648.5% | 115,403 | +612.4% | 0.01% | +700.0% |
| Q4 2015 | $1,457,000 | -72.1% | 16,200 | -71.3% | 0.00% | -75.0% |
| Q3 2015 | $5,221,000 | +181.3% | 56,491 | +199.4% | 0.00% | +300.0% |
| Q2 2015 | $1,856,000 | -32.4% | 18,870 | -31.1% | 0.00% | -50.0% |
| Q1 2015 | $2,744,000 | -66.1% | 27,375 | -68.8% | 0.00% | -60.0% |
| Q4 2014 | $8,097,000 | – | 87,638 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |